Loading
Viveve Medical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Scheller Patricia, was filed 27 Jan 2016.
Viveve Medical, Inc.: what insiders have been doing
Viveve Medical, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Viveve Medical, Inc. has had no insider filing for more than a year; the last one goes back to 17 December 2021.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€83
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$6.4M
Gross profitUS$620k10% margin
EBITDA-US$19.6M-306% margin
Net income-US$26.7M-415.8% margin
Valuation
P/Book0.0x
Beta-43.52
Balance sheet & cash
Market capUS$2.1k
Total debtUS$5.3M
Free Cash Flow-US$13.3M
Debt / Equity508%
Profitability & ownership
ROE-211.0%
ROA-62.1%
% insiders0.0%
% institutions0.0%
Last declaration on 17 December 2021
Declarations4 total
2 shares@ US$1.40100.0% of flowCommon StockSEC:0001437749-21-028890:0
28 shares@ US$1.41100.0% of flowCommon StockSEC:0001437749-21-028891:0
36 shares@ US$1.43100.0% of flowCommon StockSEC:0001437749-21-028889:0
1,428 sharesCommon StockSEC:0001437749-16-024186:0
Canonical exit: 24 Apr 2016 (T+90)
4 of 4 declarations
About Viveve Medical, Inc.
Viveve Medical, Inc. is a U.S.-based medical device company historically listed on the NASDAQ market in the United States. The company has been positioned in a highly specialized corner of women’s health and minimally invasive medical technology, centered on its proprietary cryogen-cooled monopolar radiofrequency platform (CMRF). Its core product, the Viveve System, consists of a radiofrequency generator, a handpiece, and a treatment tip. In international markets, the company has described uses related to women’s intimate health, including treatments aimed at improving vaginal laxity, sexual function, or certain urinary symptoms, depending on local regulatory clearances or approvals. In the United States, however, the SEC filings cited a different, narrower indication tied to general surgical procedures for electrocoagulation and hemostasis.
The business was built in the 2000s and later reshaped through a reverse merger, giving it a long but uneven corporate history. Its principal operating location disclosed in SEC filings is Englewood, Colorado, reinforcing that it is a domestic U.S. issuer even though its commercial strategy has historically included an international footprint through subsidiaries such as Viveve, Inc. and Viveve BV. The company has also relied on direct sales and physician-facing commercialization rather than a broad consumer model, which is typical for a device company targeting a clinical niche.
Read moreShow less
From a competitive standpoint, Viveve operates in a small, highly regulated, and fragmented segment of the medical device industry. Its differentiation has been based on technology rather than scale, and it has faced competition from alternative energy-based devices, surgical options, and other women’s health solutions. For investors, this means the company’s competitive moat has been more clinical and intellectual-property-driven than distribution-driven. As a result, the investment case is usually framed around device adoption, reimbursement and regulatory dynamics, and the company’s ability to sustain commercial execution with limited resources.
Recent developments indicate elevated financial and market risk. Nasdaq announced the delisting of Viveve Medical’s common stock, which is a material event for any public issuer and typically signals severe market-cap, compliance, or liquidity pressure. That development, combined with the company’s micro-cap profile, suggests a business under restructuring stress rather than a stable growth platform. For French, Belgian, and Swiss investors, Viveve should therefore be viewed as a speculative MedTech name with limited operating visibility, significant listing risk, and a value proposition that depends primarily on whether its technology and remaining assets can be preserved and monetized in a post-listing environment.
